Lymphoma

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

Monjuvi and Revlimid attained extended remission and improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.

Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.

Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

For patients with early-stage, unfavorable-risk Hodgkin lymphoma, this treatment option may allow for the reduction or elimination of radiotherapy in patients without malignant disease.

The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

From a college student who survived lymphoma biking 4,000 miles for charity to the death of “Harry Potter” actress Helen McCrory, here’s what’s happening in the cancer landscape this week.

Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.

Lymphoma survivor Nina Luker talks about receiving a diagnosis at age 24 and how sharing her story with nearly 200,000 supporters on social media helped her find purpose.

Early findings show that glofitamab may be a safe and effective option for patients with pretreated, relapsed/refractory B-cell non-Hodgkin lymphoma.

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.

Nearly one year ago to the day, 24-year-old Nina Luker was completely blindsided by a diagnosis of non-Hodgkin lymphoma. But after powering through treatments in the thick of the COVID-19 pandemic, Luker is now cancer-free and offering advice to those who may be looking for ways to help their loved ones through difficult times of their own.

Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment.

One patient with breast implant-associated anaplastic large cell lymphoma spoke out for herself throughout therapy — and encourages other patients do the same.

The Food and Drug Administration on Friday approved Breyanzi, a cell-based gene therapy, for the treatment of adults with certain types of large B-cell lymphoma.

This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.

Study results also determined that immune system status before treatment may predict outcomes post-treatment.